A Phase 2 Study of Idarubicin Based Combined Modality Therapy in Primary Central Nervous System Lymphoma
This clinical research study looked at a new combination of chemotherapy drugs (Idarubicin and Methotrexate) followed by a lower dose of radiotherapy in participants with Primary Central Nervous System Lymphoma (PCNSL). The main purpose of this study was to assess the effectiveness of this treatment and its effect on the ability of patients to perform normal daily functions. In addition the acute effects of the chemotherapy was assessed.
Primary Sponsor
Trans Tasman Radiation Oncology Group (TROG)
Collaborating Groups
ALLG, Amgen (Neupogen)
Final Accrual
20
Trial Chairperson
Dr Peter O’Brien, Calvary Mater Newcastle, NSW
Clinical Trial Registration
Related Post
October 18, 2022
NINJA Radiation Therapy Trial participant tells his journey to treatment
The journey to becoming the 200th participant for the
September 6, 2022
The gift that kept on giving
The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing
